Paradigm Therapeutics, Inc.
PrivateLast Round
VC Round
Jun 18, 2025
Company Overview
Paradigm Therapeutics, Inc. is a biopharmaceutical company that develops innovative topical therapies for the treatment of rare diseases, specifically Epidermolysis Bullosa.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paradigm Therapeutics, Inc. Comparables
Compare Paradigm Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CSA Biotechnologies | 56% | |
| Patagonia Pharmaceuticals, LLC | 54% | |
| Mariposa Therapeutics | 43% |
Paradigm Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 18, 2025 | ||||
| VC Round | May 6, 2025 |
Paradigm Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eshelman Ventures | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2025
$13M round led by Eshelman Ventures.
- May 6, 2025
$13M round led by Eshelman Ventures
Recent news
Latest coverage and updates
- recognized_asOct 13, 2026
Paradigm Therapeutics is named a finalist for the 2026 Prix Galien USA “Best Start-Up” Award, marking its second consecutive nomination, in South Carolina on Oct. 13th '26; The Galien Foundation manages the award.
- receives_awardOct 13, 2026
Paradigm Therapeutics is named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award by The Galien Foundation for SD-101, marking its second consecutive nomination, on Oct 13th '26 in South Carolina.
Paradigm Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Paradigm Therapeutics, Inc.'s valuation, stock price, and market status.
Is Paradigm Therapeutics, Inc. a public or private company?
Paradigm Therapeutics, Inc. is a private company.
What is the current stock price of Paradigm Therapeutics, Inc.?
Paradigm Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Paradigm Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Paradigm Therapeutics, Inc. worth (valuation)?
Valuation information for Paradigm Therapeutics, Inc. is not publicly available.
Can I buy Paradigm Therapeutics, Inc. stock?
Paradigm Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Paradigm Therapeutics, Inc.'s last funding round?
Paradigm Therapeutics, Inc.'s most recent funding round was VC Round on June 18, 2025.
Who are the main investors in Paradigm Therapeutics, Inc.?
Key investors in Paradigm Therapeutics, Inc. include Eshelman Ventures.
Will Paradigm Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Paradigm Therapeutics, Inc..
How can I track Paradigm Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Paradigm Therapeutics, Inc.'s shares on secondary markets.